Identification of Five Driver Gene Mutations in Patients with Treatment-Naïve Lung Adenocarcinoma in Taiwan

Kuo-Hsuan Hsu, Chao-Chi Ho, Te-Chun Hsia, Kang-Yi Su, Ming-Fang Wu, Kuo-Liang Chiu, Tsung-Ying Yang, Kun-Chieh Chen, Hean Ooi, Tzu-Chin Wu, Hung-Jen Chen, Hsuan-Yu Chen, Chi-Sheng Chang, Chung-Ping Hsu, Jiu-Yi Hsia, Cheng-Yen Chuang, Chin-Hung Lin, Jeremy J. W. Chen, Kuan-Yu Chen, Wei-Yu Liao, Jin-Yuan Shih, Sung-Liang Yu, Chong-Jen Yu, Pan-Chyr Yang, Gee-Chen Chang

1 Division of Critical Care and Respiratory Therapy, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan, 2 Institute of Biomedical Sciences, National Chung Hsing University, Taichung, Taiwan, 3 Division of Pulmonary Medicine, Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan, 4 Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, 5 Department of Respiratory Therapy, China Medical University, Taichung, Taiwan, 6 Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan, 7 Department of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei, Taiwan, 8 Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan, 9 Divisions of Medical Oncology and Pulmonary Medicine, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan, 10 School of Medicine, Chung Shan Medical University, Taichung, Taiwan, 11 Division of Chest Medicine, Department of Internal Medicine, Taichung Tzu-Chi Hospital, Taichung, Taiwan, 12 School of Post-baccalaureate Chinese Medicine, Tzu Chi University, Hualien, Taiwan, 13 Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan, 14 Department of Critical Care Medicine, Taichung Tzu-Chi Hospital, Taichung, Taiwan, 15 Department of Medical Imaging and Radiological Sciences, Central Taiwan University of Science and Technology, Taichung, Taiwan, 16 Department of Medical Research, China Medical University Hospital, China Medical University, Taichung, Taiwan, 17 School of Medicine, Tzu Chi University, Hualien, Taiwan, 18 Division of Pulmonary Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan, 19 Division of Pulmonary and Critical Care Medicine, China Medical University Hospital, Taichung, Taiwan, 20 Institute of Statistical Science, Academia Sinica, Taipei, Taiwan, 21 Division of Thoracic Surgery, Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan, 22 School of Medicine, National Yang-Ming University, Taipei, Taiwan, 23 Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan, 24 NTU Center for Genomic Medicine, National Taiwan University College of Medicine, Taipei, Taiwan, 25 Department of Pathology and Graduate Institute of Pathology, College of Medicine, National Taiwan University, Taipei, Taiwan, 26 Center for Optoelectronic Biomedicine, College of Medicine, National Taiwan University, Taipei, Taiwan

These authors contributed equally to this work.
‡ These authors are co-first authors on this work.
¶ These authors contributed equally to this work as co-corresponding authors.
* slyu@ntu.edu.tw (SLY); jefferycjyu@ntu.edu.tw (CJY); august@vghtc.gov.tw (GCC)

Abstract

Background

It is important to select appropriate targeted therapies for subgroups of patients with lung adenocarcinoma who have specific gene alterations.
Methods
This prospective study was a multicenter project conducted in Taiwan for assessment of lung adenocarcinoma genetic tests. Five oncogenic drivers, including EGFR, KRAS, BRAF, HER2 and EML4-ALK fusion mutations, were tested. EGFR, KRAS, BRAF and HER2 mutations were assessed by MALDI-TOF MS (Cohort 1). EML4-ALK translocation was tested by Ventana method in EGFR-wild type patients (Cohort 2).

Results
From August 2011 to November 2013, a total of 1772 patients with lung adenocarcinoma were enrolled. In Cohort 1 analysis, EGFR, KRAS, HER2 and BRAF mutations were identified in 987 (55.7%), 93 (5.2%), 36 (2.0%) and 12 (0.7%) patients, respectively. Most of these mutations were mutually exclusive, except for co-mutations in seven patients (3 with EGFR + KRAS, 3 with EGFR + HER2 and 1 with KRAS + BRAF). In Cohort 2 analysis, 29 of 295 EGFR-wild type patients (9.8%) were positive for EML4-ALK translocation. EGFR mutations were more common in female patients and non-smokers and KRAS mutations were more common in male patients and smokers. Gender and smoking status were not correlated significantly with HER2, BRAF and EML4-ALK mutations. EML4-ALK translocation was more common in patients with younger age.

Conclusion
This was the first study in Taiwan to explore the incidence of five oncogenic drivers in patients with lung adenocarcinoma and the results could be valuable for physicians in consideration of targeted therapy and inclusion of clinical trials.

Introduction
Lung cancer is the leading cause of cancer-related death worldwide [1], as well as in Taiwan. To improve the survival for advanced lung adenocarcinoma, strategies to target driver gene alterations are important and currently under intensive investigation.

Several molecular alterations are known to be involved in tumorigenesis of lung adenocarcinoma, such as epidermal growth factor receptor (EGFR), Kirsten rat sarcoma viral oncogene homolog (KRAS), v-raf murine sarcoma viral oncogene homolog B (BRAF), human epidermal growth factor receptor 2 (HER2), and echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) fusion mutations. Mutations in these genes are responsible for both the initiation and maintenance of lung adenocarcinoma [2]. By understanding the biological functions of these driver genes, it may be possible to develop specific therapies for lung cancer with known driver gene mutations.

Recently, Kris et al. demonstrated that patients with an oncogenic driver mutation who received the corresponding targeted therapy had a significantly longer survival time than those with a driver mutation who did not receive the targeted therapy and those without a driver mutation [3]. In comparison with chemotherapy, EGFR-tyrosine kinase inhibitors (TKI), including gefitinib, erlotinib and afatinib, have provided a better outcome and quality of life for patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC) and have become
one of the standard first line therapies [4–6]. Similar efficacy was observed in EML4-ALK positive lung cancer patients treated with crizotinib and second-generation ALK inhibitors [7,8].

Many drugs are available now and more will be developed for patients with specific driver gene mutations. Therefore, we decided to conduct a prospective study in five medical centers in Taiwan to explore the incidence of driver gene mutations and to define subgroups of patients in whom candidate driver gene alterations are enriched. Analyses of five driver genes, including EGFR, KRAS, BRAF, HER2 and EML4-ALK, were performed in patients with treatment naive lung adenocarcinoma.

Materials and Methods

Patients

This multicenter prospective observational study was conducted in five medical centers in Taiwan, including Taichung Veterans General Hospital, National Taiwan University Hospital, China Medical University Hospital, Chung Shan University Hospital and Taichung Tzu Chi Hospital. To be eligible for the study, patients were required to have treatment-naïve and pathologically confirmed lung adenocarcinoma and available tumor specimens for genetic analysis. Patients were excluded if they had lung cancer with histology other than adenocarcinoma, including those with carcinoma not otherwise specified (NOS), or other active malignancy. This study was approved by the Institutional Review Board of the participating institutes, including, Institutional Review Board of Taichung Veterans General Hospital (IRB No. C08197), National Taiwan University Hospital Research Ethics Committee (IRB No. 201111039RIC), Institutional Review Board of Chung Shan Medical University Hospital (IRB No. CS12022), China Medical University and Hospital Research Ethics Committee (IRB No. DMR100-IRB-284[CR-2]) and Taichung Tzu Chi Hospital Research Ethics Committee (IRB No. REC102–7). Written informed consents for genetic testing and clinical data records were obtained from all patients.

Identification of driver mutations

Five oncogenic drivers, including EGFR, KRAS, BRAF, HER2 and EML4-ALK, were tested. EGFR, KRAS, BRAF and HER2 mutations were assessed by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) since August 2011. EML4-ALK translocation was tested by Ventana method in patients with EGFR-wild type lung adenocarcinoma from July 2013. All the tests were performed by ISO15189-certified TR6 Pharmacogenomics Lab (PGL), National Research Program for Biopharmaceuticals (NRPB), the National Center of Excellence for Clinical Trial and Research of NTUH.

Tumor specimens were procured for EGFR, KRAS, BRAF and HER2 mutation analyses as previously described [9]. Briefly, DNA was extracted from the tumors using a QIAmp DNA Mini kit (Qiagen, Valencia, CA) following the manufacturer’s protocol. The genetic alterations of EGFR, KRAS, BRAF and HER2 were detected by MALDI-TOF MS based on the methods used in our previous reports with modifications [10,11]. Briefly, we expanded the multiplex gene-testing panel to include EGFR, KRAS, BRAF and HER2 genes. We performed the analysis according to manufacturer’s protocol for MassARRAY system (Sequenom, San Diego, CA). In the biochemical reaction, polymerase chain reaction (PCR) followed by single nucleotide extension was performed by using primers and corresponding detection probes to amplify the region containing each target mutation. After SpectroClean Resin clean up, samples were loaded onto the matrix of SpectroCHIP by Nanodispenser (Matrix) and then analyzed by Bruker Autoflex MALDI-TOF MS. Data were collected and analyzed by Typer 4 software (Sequenom, San Diego, CA). The PCR primers and probes used in the present study were summarized in S1 Table.
Because EGFR mutations and EML4-ALK translocations are almost mutually exclusive [12], assessment of EML4-ALK translocations was only performed in patients with EGFR-wild type lung adenocarcinoma in this project by Ventana method [13]. Briefly, the assay (Ventana IHC, Ventana, Tucson, AZ) was a fully automated IHC assay developed by Ventana, using the pre-diluted Ventana anti-ALK (D5F3) Rabbit monoclonal primary antibody, together with the Optiview DAB IHC detection kit and Optiview Amplification kit on the Benchmark XT stainer. Each specimen was also stained with a matched Rabbit Monoclonal Negative Control Immunoglobulin antibody. The manufacturer’s scoring algorithm was a binary scoring system (positive or negative for ALK status), which we adopted for evaluating the staining results. Neoplastic cells labeled with the ALK IHC assay were evaluated for presence or absence of the DAB signal. Presence of strong granular cytoplasmic staining in tumor cells (any percentage of positive tumor cells) was deemed to be ALK positive, while absence of strong granular cytoplasmic staining in tumor cells was deemed to be ALK negative.

Data records and response evaluation
Activating mutation of EGFR gene is the most common genetic alteration in lung adenocarcinoma in East Asians [14]. Therefore, in addition to exploration of the incidence of driver mutations, we also evaluated the efficacy of EGFR-TKI in patients with EGFR-mutant lung adenocarcinoma. Clinical data for analysis included patients’ age, gender, Eastern Cooperative Oncology Group performance status (ECOG PS), tumor stage and smoking status. TNM (tumor, node, and metastases) staging was done according to the 7th edition of the American Joint Committee for Cancer (AJCC) staging system [15]. Chest computed tomographies (CT), including the liver and adrenal glands, and other required imaging studies for response evaluation were reviewed by two chest physicians. Unidimensional measurements as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 were used in this study [16].

Statistical methods
Univariate analyses by Fisher’s exact test and Pearson Chi-square test were conducted on the frequency of five oncogenic drivers and on the objective response rate (ORR) and disease control rate (DCR) of EGFR-TKI therapy to evaluate the effects of clinical factors relating to patient and disease characteristics. Multivariate analyses of ORR and DCR were performed using logistic regression model. The Kaplan—Meier method was used to estimate progression-free survival (PFS) and overall survival (OS). Differences in survival time were analyzed using the log-rank test. Multivariate analyses of PFS and OS were performed using Cox proportional hazard model. All statistical tests were done with SPSS 15.0 (SPSS, Chicago, IL). Two-tailed tests and p values <0.05 for significance were used.

Results
Patient characteristics
From August 2011 to November 2013, a total of 1772 patients with treatment-naïve lung adenocarcinoma were enrolled as Cohort 1 for EGFR, KRAS, BRAF and HER2 genetic analyses. With the development of Ventana method in July 2013 and the availability of tumor tissues, EML4-ALK translocation testing was performed in total 295 patients with EGFR-wild type lung adenocarcinoma, who were enrolled as Cohort 2. The baseline characteristics are shown in Table 1. Briefly, in Cohort 1, the median age was 58 years (range 21–100), 821 patients (46.3%) were male, 1179 patients (66.5%) were non-smokers and 1248 patients (70.4%) had advanced stage diseases (stage IIIb or IV). In Cohort 2, the median age was 61 years (range
(21–100), 150 patients (50.8%) were male, 177 patients (60.0%) were non-smokers and 198 patients (67.1%) had advanced stage diseases.

Incidence of five oncogenic drivers

The oncogenic driver mutations detected in the present study are summarized in Table 2. The incidence of five driver gene mutations is shown in Fig. 1 and Table 2. In the Cohort 1 analysis, 987 of 1772 lung adenocarcinoma patients (55.7%) harbored activated EGFR mutations, which accounted for the majority of diver gene mutations. Mutations in KRAS, HER2 and BRAF genes were identified in 93 (5.2%), 36 (2.0%) and 12 (0.7%) patients, respectively. A total of 651 patients (36.7%) had no detectable driver gene mutation. Majority of the genetic alterations were mutually exclusive, except for co-mutations in seven (0.4%) patients (3 with EGFR and KRAS mutations, 3 with EGFR and HER2 mutations and 1 with KRAS and BRAF mutations). In the Cohort 2 analysis, 29 of 295 patients with EGFR-wild type lung adenocarcinoma (9.8%) were found to have EML4-ALK translocation and none of them harbored other driver gene mutations.

Association between patient characteristics and driver gene mutations

The analysis of association between patient characteristics and driver gene mutations is shown in Table 3. For EGFR mutations, a significantly higher mutation rate was noted in female then in male patients (65.2 vs. 44.7%, $P < 0.001$) and in non-smokers then in smokers.
In Cohort 2 analysis, age was the only factor that correlated significantly with EML4-ALK translocation and patients with younger age (<65 years) had a higher mutation rate than patients aged more than 65 years (14.0 vs. 3.4%, P = 0.002). Moreover, we observed a trend toward a higher mutation rate in non-smokers compared with smokers (11.9 vs. 6.8%) but the trend did not reach a level of significance (P = 0.167). Neither age nor tumor stage was correlated significantly with EML4-ALK translocation.

Efficacy of EGFR-TKI in EGFR-mutant lung adenocarcinoma

In total, 352 patients who had EGFR-mutations and lesions that could be measured for treatment responses received EGFR-TKI therapy as the first line treatment (336 with gefitinib and 16 with erlotinib). The drug prescribed was chosen by the physicians in charge. Three patients achieved complete response, 203 patients achieved partial response, 95 patients had stable disease and 51 patients had progressive disease. The ORR and DCR were 58.5% and 85.5%, respectively. Univariate analyses of ORR and DCR are shown in Table 4. Patients with exon 19 deletions were associated with a higher ORR than those with L858R and other uncommon mutations (68.2 vs. 51.2 vs. 48.0%, P = 0.004). No other factors correlated significantly with ORR.

In DCR analysis, females, non-smokers, patients with better ECOG PS (0–1) and those with exon 19 deletions were associated with a significantly higher DCR (P = 0.001, 0.013, <0.001 and 0.004, respectively). In multivariate logistic regression model, the exon 19 deletion was the only factor that predicted both a higher ORR (odds ratio 2.04, 95% CI 1.31–3.17, P = 0.002) and a higher DCR (odds ratio 2.40, 95% CI 1.21–4.77, P = 0.012). Gender and ECOG PS (0–1) remained significantly correlated with DCR in multivariate analysis (data not shown).

Table 2. Characteristics of genetic alterations assessed in the present study.

| Gene* | Exon/Domain | Patient No. | Assessed genetic alterations |
|-------|-------------|-------------|-----------------------------|
| *EGFR | Exon 18     | 18          | E709A, E709G, E709V          |
|       | Exon 19     | 434         | E746-A750del, E746-T751>A,  |
|       |             |             | E746-S752>V, L747-A750>P, L747-T751>P, |
|       |             |             | L747-S752del, L747-T751del, L747-P753>S, |
|       |             |             | E746-T751>I, E746-T751del, E746-S752>A,  |
|       |             |             | E746-S752>D, L747-A750>P, L747-T751>Q,  |
|       |             |             | L747-E749del, L747-P753>Q, L747-T751>S |
|       | Exon 20     | 3           | T790M, S768I                  |
|       | Exon 21     | 483         | L858R, L858Q, L861Q           |
|       | Exon 18–21  | 49          | Complex mutations             |
| *KRAS | Codon 12    | 89          | G12S, G12R, G12C, G12D, G12A, G12V |
|       | Codon 13    | 4           | G13S, G13C, G13R, G13D, G13V, G13A |
| *HER2 | Exon 20     | 36          | A775-G776insYVMA              |
| *BRAF | Exon 15     | 12          | V600E                        |
| *ALK  | N/A         | 29          | EML4-ALK translocation        |

EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; EML4, echinoderm microtubule-associated protein like 4.

*Cohort 1 (1772 patients with lung adenocarcinoma) testing of EGFR, KRAS, HER2 and BRAF mutations and cohort 2 (295 patients with EGFR-wild type lung adenocarcinoma) testing of EML4-ALK translocation.
The median PFS and OS were 11.6 (95% CI 10.0–13.2) and 39.4 (95% CI not applicable) months, respectively. In the univariate analysis, non-smokers and patients with ECOG PS 0–1 were associated with a significant longer PFS and ECOG PS (0–1) was the only factor that predicted a longer OS significantly (data not shown). Although patients harbored exon 19 deletions were associated with both a higher ORR and DCR, neither PFS (HR 0.74, 95% CI 0.55–1.00, P = 0.053) nor OS (HR 0.70, 95% CI 0.42–1.16, P = 0.163) was significantly correlated with EGFR mutation types in multivariate analysis. In multivariate Cox proportional hazard model, ECOG PS (0–1) was the only factor that independently predicted both a longer PFS (HR 0.67, 95% CI 0.46–0.97, P = 0.034) and OS (HR 0.46, 95% CI 0.27–0.79, P = 0.005).
Discussion

The success of EGFR and ALK inhibitor therapies in lung cancer patients with EGFR mutations and EML4-ALK translocations initiated the era of targeted therapy in advanced NSCLC [5,8] and shifted treatment from platinum-based chemotherapy to molecularly targeted therapy. Recent genomic studies in lung adenocarcinoma have identified other potential therapeutic targets, such as mutations in KRAS, HER2 and BRAF, ROS1 rearrangements, RET fusions and MET amplification [17,18]. As the current trend of NSCLC treatment, especially lung adenocarcinoma, has been shifted from tumor stage-based to more individualized therapies based on histological and molecular characteristics [19], the increasing importance of genomic information should prompt physicians to obtain adequate tissue specimens when planning diagnostic procedures [20].

In East Asia, there are several unique characteristics of lung cancer [21], including the predominance of adenocarcinoma over other cell types and a large proportion of never smoker and female patients. Such features may provide keys to further investigate the treatment or prevention of lung cancer in East Asians. Moreover, the incidences of activating mutations of oncogenic drivers in Western and Asian populations are different, especially the EGFR and KRAS mutations [3,18,22,23]. In the present study, we showed that the incidence of EGFR mutations in Taiwanese lung adenocarcinoma patients was 55.7%, which was similar to the results of PI-ONEER study [14]. EGFR mutation is the most important biomarker for predicting the
outcome of EGFR-TKI therapy. In the present study, the ORR of EGFR-TKI therapy was 58.5%, which was slightly lower than that of randomized controlled trials. However, we also enrolled patients with poor ECOG PS (2 or more) and outcome with regard to DCR, PFS and OS was similar to previous studies [4,5]. The incidence of KRAS mutation in the present study was only 5.0%, much lower than that reported in Caucasians and even lower than that in other Asian countries [18,22]. Since there is a significant association between KRAS mutations and smoking behaviors [22,24], the relatively high rate of non-smoking lung cancers in Taiwan might be one reason for the lower KRAS mutation rate in the present study. Herein, our results disclosed the higher EGFR mutation rate in female and non-smokers and higher KRAS mutation rate in male and smokers, which were in line with the results of previous studies [24,25].

KRAS mutations in lung adenocarcinoma consist of single amino acid substitutions in hotspots located mostly in codon 12 and rarely in codons 13 and 61 [26,27]. In our study, codon 12 and codon 13 mutations were detected, with much higher mutation rate in codon 12 than in codon 13 (95.7% vs. 4.3%). There is evidence that different KRAS mutant proteins have differing clinical significance. In previous study, either G12C or G12V-mutant KRAS predicted shorter progression free survival to EGFR-TKI compared to wild type or other KRAS mutations [28]. Despite the lack of effective KRAS-targeted agents currently, detection of KRAS mutations could be considered to apply in clinical practice for its prognostic value [29,30].

The rate of BRAF V600E mutation was 0.7% (12/1772) in the present study with eight non-smokers and four smokers. In the study by An et al., BRAF mutation rate was 2.3% (7/307) in lung adenocarcinoma, while BRAF exon 15 mutation rate was 0.98% (3/307) [31]. The BRAF V600E mutation rate was similar to that in our study. Our results showed that there was no significant association of BRAF V600E mutation with patients’ age, gender, smoking status or...
tumor stage. This differs from a recent meta-analysis by Chen et al. [32], showing that BRAF V600E mutation was significantly correlated with female gender and non-smoking history. Because different cohorts of patients and detection methods potentially confound the screening of uncommon mutations, further studies are needed to clarify the nature of BRAF mutations.

Although BRAF mutations are uncommon, they represent an important therapeutic target due to the availability of individualized therapies in clinical use for melanoma and the promising results reported in ongoing clinical trials for NSCLC patients [33].

HER2 mutations consist of in-frame insertions in exon 20, especially HER2YVMA mutant, leading to constitutive activation of the receptor and downstream AKT and MEK pathways [34]. HER2 mutations meet the definition of genetic driver and the concept of transforming property of such a genetic alteration has been proved in preclinical models [35]. In the study by Mazieres et al., HER2 mutation was identified in 65 (1.7%) of 3800 patients tested with a high proportion of women (69%) and never-smokers (52.3%) [36]. In our study, similar HER2 mutation rate (2.0%) was found with a higher mutation rate in patients with advanced stage diseases. As several agents might be active in HER2-mutant lung adenocarcinoma, it is important to screen for HER2 mutations for the potential efficacy of HER2-targeted medications.

ALK rearrangement has been demonstrated to be a potent oncogenic driver and a promising therapeutic target in NSCLC. The rate of ALK rearrangements ranged from 3 to 7% of patients harboring EGFR mutations (n = 352).

### Table 4. Univariate analysis of objective response rate and disease control rate in patients harboring EGFR mutations (n = 352).

|                         | Patient No. | ORR (%) | P value | DCR (%) | P value |
|-------------------------|-------------|---------|---------|---------|---------|
| Age (yrs)               |             |         |         |         |         |
| ≤ 65                    | 189         | 56.6    | 0.449   | 85.2    | 0.880   |
| > 65                    | 163         | 60.7    |         | 85.9    |         |
| Gender                  |             |         |         |         |         |
| Male                    | 131         | 53.4    | 0.147   | 77.1    | 0.001   |
| Female                  | 221         | 61.5    |         | 90.5    |         |
| Smoking                 |             |         |         |         |         |
| Non-smokers             | 266         | 60.5    | 0.208   | 88.3    | 0.013   |
| Current/former smokers  | 86          | 52.3    |         | 76.7    |         |
| ECOG PS<sup>a</sup>     |             |         |         |         |         |
| 0–1                     | 289         | 58.5    | 0.660   | 88.6    | <0.001  |
| ≥ 2                     | 57          | 54.4    |         | 68.4    |         |
| Stage                   |             |         |         |         |         |
| IIb                     | 12          | 50.0    | 0.564   | 75.0    | 0.393   |
| IV                      | 340         | 58.8    |         | 85.9    |         |
| Mutation types          |             |         |         |         |         |
| Exon 19 deletions       | 157         | 68.2    | 0.004   | 91.1    | 0.004   |
| Exon 21 L858R           | 170         | 51.2    |         | 82.9    |         |
| Others                  | 25          | 48.0    |         | 68.0    |         |
| EGFR-TKIs               |             |         |         |         |         |
| Gefitinib               | 336         | 58.0    | 0.448   | 84.8    | 0.142   |
| Erlotinib               | 16          | 68.8    |         | 100     |         |

EGFR, epidermal growth factor receptor; ORR, objective response rate; DCR, disease control rate; ECOG PS, ECOG PS, Eastern Cooperative Oncology Group performance status.

*Mutation types by Pearson Chi-square test; otherwise by Fisher’s exact test.

<sup>a</sup>Exclude 6 cases with missing ECOG PS data.

doi:10.1371/journal.pone.0120852.t004
unselected patients with NSCLC [37–39]. Similar to EGFR mutations, ALK rearrangements are associated with distinct clinical features, including younger age at diagnosis, never of light smokers and adenocarcinoma histology. Phase 3 study of crizotinib in previously treated patients with ALK-rearranged advanced NSCLC showed an ORR of 65% and a PFS of 7.7 months, which was significantly superior to the results with standard chemotherapy [8].

FISH analysis is the only approved diagnostic test to detect break-apart signals in ALK rearrangement. However, the apparatuses required for FISH analysis may not be available in all diagnostic laboratories. IHC can be an alternative to FISH and using the highly sensitive detection methods in combination with high affinity antibodies, IHC can effectively detect ALK fusion protein in lung adenocarcinoma with high sensitivity and specificity [40,41]. Automated IHC assay system devised by Ventana was used in this study. Ying et al. assessed 196 lung adenocarcinomas using Ventana IHC, FISH, Cell Signaling Technology (CST) IHC and RT—PCR and the results showed that 65 (33%), 63 (32%), 70 (36%) and 69 (35%) cases were ALK positive, respectively [13]. The sensitivity and specificity of Ventana IHC were 100% and 98%. The automated Ventana IHC system is desirable to be considered as a guide to prescribe ALK inhibitors treatment, as IHC is a routine methodology in most pathology laboratories to detect a protein of interest. In the case of the availability of tumor tissues, our results may be slightly skewed due to the small sample size tested for ALK rearrangements.

In the present study, around 35% of lung adenocarcinoma patients did not have detectable oncogenic drivers. The comprehensive molecular profiling of 230 resected lung adenocarcinomas reported recently by Cancer Genome Atlas Research Network also showed that 24.4% of patients had no detectable driver oncogenic mutations at initial identification of candidate driver genes [17].

In summary, our study demonstrates that lung adenocarcinoma defined by specific driver gene alterations could be considered as different diseases. The identification of driver mutations has heralded a new era of targeted therapy in lung adenocarcinoma with currently available and potentially targetable genetic aberrations.

Supporting Information
S1 Table. The PCR primers and probes used to genetic analysis in the present study.

(PDF)

Acknowledgments
We would like to thank the Comprehensive Cancer Center of Taichung Veterans General Hospital for the assistance in data collection and management and Pharmacogenometics Lab of National Research Program for Biopharmaceuticals for technical service support.

Author Contributions
Conceived and designed the experiments: SLY CJY GCC. Performed the experiments: KHH CCH TCH KYS MFW KLC TYY KCC HO TCW HJC CPH JYH CYC CHL KYC WYL JYS. Analyzed the data: JST KYS HYC CSC. Contributed reagents/materials/analysis tools: JJC SLY CJY PCY GCC. Wrote the paper: KHH CCH TCH JST.

References
1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64: 9–29. doi: 10.3322/caac.21208 PMID: 24399786
2. Bronte G, Rizzo S, La Paglia L, Adamo V, Siragusa S, Ficorella C, et al. Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. Cancer Treat Rev. 2010; 36 Suppl 3: S21–29. doi: 10.1016/S0305-7372(10)70016-5 PMID: 21129606

3. Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014; 311: 1998–2006. doi: 10.1001/jama.2014.3741 PMID: 24846037

4. Lee CK, Brown C, Gralla RJ, Hirsh V, Thongprasert S, Tasi CM, et al. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst. 2013; 105: 595–605. doi: 10.1093/jnci/djt072 PMID: 23594426

5. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361: 947–957. doi: 10.1056/NEJMoa0810699 PMID: 19692680

6. Thongprasert S, Duffield E, Saijo N, Wu YL, Yang JC, Chu DT, et al. Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS). J Thorac Oncol. 2011; 6: 1872–1880. doi: 10.1097/JTO.0b013e31822dadaf7 PMID: 22011650

7. Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014; 370: 1189–1201. doi: 10.1056/NEJMoa1311107 PMID: 24670165

8. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013; 368: 2385–2395. doi: 10.1056/NEJMoa1214886 PMID: 23724913

9. Tseng JS, Wang CL, Huang MS, Chen CY, Chang CY, Yang TY, et al. Impact of EGFR Mutation Detection Methods on the Efficacy of Erlotinib in Patients with Advanced EGFR-Wild Type Lung Adenocarcinoma. PLoS One. 2014; 9: e107160. doi: 10.1371/journal.pone.0107160 PMID: 25215536

10. Su KY, Chiu HC, Kuo ML, Yang JC, Chan WK, et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol. 2012; 30: 433–440. doi: 10.1200/JCO.2011.38.3224 PMID: 22215752

11. Tsai TH, Su KY, Wu SG, Chang YL, Luo SC, Jan IS, et al. RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer. Eur Respir J. 2012; 39: 677–684. doi: 10.1183/09031996.0043511 PMID: 21719485

12. Sasaki T, Rodig SJ, Chirieac LR, Janne PA. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer. 2010; 46: 1773–1780. doi: 10.1016/j.ejca.2010.04.002 PMID: 20418096

13. Ying J, Guo L, Qiu T, Shan L, Ling Y, Liu X, et al. Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma. Ann Oncol. 2013; 24: 2589–2593. doi: 10.1093/annonc/mdt295 PMID: 23904459

14. Shi Y, Au JS, Thongprasert S, Srinivasan S, Tsai CM, Khoa MT, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014; 9: 154–162. doi: 10.1097/JTO.0000000000000333 PMID: 24419411

15. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC Cancer Staging Handbook. 7th ed. New York: Springer; 2009.

16. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45: 228–247. doi: 10.1016/j.ejca.2008.10.002 PMID: 19097774

17. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014; 511: 543–550. doi: 10.1038/nature13385 PMID: 25079552

18. Seo JS, Ju YS, Lee WC, Shin JY, Lee JK, Bleazard T, et al. The transcriptional landscape and mital profile of lung adenocarcinoma. Genome Res. 2012; 22: 2109–2119. doi: 10.1101/gr.145144.112 PMID: 22975805

19. West H, Harpole D, Travis W. Histologic considerations for individualized systemic therapy approaches for the management of non-small cell lung cancer. Chest. 2009; 136: 1112–1118. doi: 10.1378/chest.08-2484 PMID: 19809052

20. Cardarella S, Johnson BE. The impact of genomic changes on treatment of lung cancer. Am J Respir Crit Care Med. 2013; 188: 770–775. doi: 10.1164/rccm.201305-0843PP PMID: 23841470

21. Bell DW, Brannigan BW, Matsuo K, Finkelstein DM, Sordella R, Settleman J, et al. Increased prevalence of EGFR-mutant lung cancer in women and in East Asian populations: analysis of estrogen-
related polymorphisms. Clin Cancer Res. 2008; 14: 4079–4084. doi:10.1158/1078-0432.CCR-07-5030 PMID: 18593984

22. Serizawa M, Koh Y, Kenmotsu H, Isaka M, Murakami H, Akamatsu H, et al. Assessment of mutational profile of Japanese lung adenocarcinoma patients by multtarget assays: a prospective, single-institute study. Cancer. 2014; 120: 1471–1481. doi: 10.1002/cncr.28604 PMID: 24700479

23. Tam IY, Chung LP, Suen WS, Wang E, Wong MC, Ho KK, et al. Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res. 2006; 12: 1647–1653. PMID: 16533793

24. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008; 455: 1069–1075. doi:10.1038/nature07423 PMID: 18948947

25. Barlesi F, Blons H, Beau-Faller M, Rouquette I, Quafik L, Mosser J, et al. Biomarkers (BM) France: Results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and EML4-ALK gene fusion assessment on the first 10,000 non-small cell lung cancer (NSCLC) patients (pts). J Clin Oncol. 2013; 31: (suppl; abstr 8000).

26. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003; 3: 11–22. PMID: 12509763

27. Rodenhuis S, Slebos RJ. Clinical significance of ras oncogene activation in human lung cancer. Cancer Res. 1992; 52: 2665s–2669s. PMID:1562997

28. Ihle NT, Byers LA, Kim ES, Saintigny P, Lee JJ, Blumenschein GR, et al. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst. 2012; 104: 228–239. doi:10.1093/jnci/djs523 PMID: 22247021

29. Perera SA, Li D, Shimamura T, Raso MG, Ji H, Chen L, et al. HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy. Proc Natl Acad Sci U S A. 2009; 106: 474–479. doi:10.1073/pnas.0808930106 PMID: 19122144

30. Shimamura T, Ji H, Minami Y, Thomas RK, Lowell AM, Shibuya K, et al. Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status. PLoS One. 2012; 7: e40109. doi: 10.1371/journal.pone.0040109 PMID: 22768234

31. Koivunen JP, Mermel C, Zejnulahu K, Murphy C, Lifshits E, Holmes AJ, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. J Clin Oncol. 2008; 16: 6487–6491. PMID: 18618618

32. Mazeres J, Peters S, Lepage B, Cortot AB, Barlesi F, Beau-Faller M, et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol. 2013; 31: 1997–2003. doi: 10.1200/JCO.2012.45.6095 PMID: 23610105

33. Kolvunen JP, Merriel C, Zejnulahu K, Murphy C, Lifshits E, Holmes AJ, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. J Clin Oncol. 2008; 14: 4275–4283. doi: 10.1186/1078-0432.CCR-08-0168 PMID: 18694010

34. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010; 363: 1693–1703. doi:10.1056/NEJMoa1006448 PMID: 20979469

35. Suda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007; 448: 561–566. PMID: 17825570
40. Mino-Kenudson M, Chirieac LR, Law K, Hornick JL, Lindeman N, Mark EJ, et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res. 2010; 16: 1561–1571. doi: 10.1158/1078-0432.CCR-09-2845 PMID: 20179225

41. Murakami Y, Mitsudomi T, Yatabe Y. A Screening Method for the ALK Fusion Gene in NSCLC. Front Oncol. 2012; 2: 24. doi: 10.3389/fonc.2012.00024 PMID: 22655265